How should we support pharmaceutical innovation?

References

• Cutler D, Deaton A, Lleras-Muney A. The determinants of mortality. J. Econ. Perspect.20(3), 97–120 (2006).
   Web of Science ®Google Scholar
• Baker D. Stagnation in the Drug Development Process: Are Patents the Problem? Center for Economic and Policy Research, DC, USA (2007).
   Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Economics22(2), 151–185 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards A. Open-source science to enable drug discovery. Drug Discov. Today13(17–18), 731–733 (2008).
   PubMed Web of Science ®Google Scholar
• Bessen J, Meurer MJ. Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk. Princeton University Press, NJ, USA (2008).
   Google Scholar
• Boldrin M, Levine DK. Against Intellectual Monopoly. Cambridge University Press, Cambridge, UK (2008).
   Google Scholar
• Boyle J. The Public Domain: Enclosing the Commons of the Mind. Yale University Press, CT, USA (2008).
   Google Scholar
• Heller MA. The Gridlock Economy: How Too Much Ownership Wrecks Markets, Stops Innovation and Costs Lives. Basic Books, NY, USA (2008).
   Google Scholar
• Jaffe AB, Lerner J. Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It. Princeton University Press, NJ, USA (2006).
   Google Scholar
• Guell R, Fischbaum M. Estimating allocative efficiency in the prescription drug industry. Applied Economic Letters4(7), 419–423 (1997).
   Web of Science ®Google Scholar
• Tamblyn R, Laprise R, Hanley JA et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA285(4), 421–429 (2001).
   PubMed Web of Science ®Google Scholar
• Schoen MD, DiDomenico RJ, Connor SE, Dischler JE, Bauman JL. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy21(12), 1455–1463 (2001).
   PubMed Web of Science ®Google Scholar
• Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int. J. Health Services34, 101–122 (2004).
   PubMed Web of Science ®Google Scholar
• Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am. J. Manag. Care11(11), 730–740 (2005).
   PubMed Web of Science ®Google Scholar
• Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am. J. Manag. Care12(9), 509–517 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. Importation and innovation. Econ. Innov. New Technol.16(6), 403–417 (2007).
   Google Scholar
• Abbott TA, Vernon JA. The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions. Manag. Decis. Econ.28, 293–306 (2007).
   Google Scholar
• US Department of Commerce. Pharmaceutical Price Controls in OECD Countries. US Department of Commerce International Trade Administration, DC, USA (2004).
   Google Scholar
• Sood N, de Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Affairs28(1), w125–w137 (2009).
   Web of Science ®Google Scholar
• Hollis A. How cheap are Canada’s drugs really? J. Pharm. Pharm. Sci.7(2), 215–216 (2004).
   PubMed Web of Science ®Google Scholar
• Hollis A, Ibbott P. How parallel trade affects drug policies and prices in Canada and the United States. Am. J. Law Med.32(2–3), 193–218 (2006).
   PubMed Web of Science ®Google Scholar
• Grootendorst P. The economics of cross border trade in pharmaceuticals: theory and evidence. J. Pharm. Marketing Manag.16(3), 99–109 (2004).
   Google Scholar
• Bart TN. Parallel trade of pharmaceuticals: a review of legal, economic, and political aspects. Value in Health11(5), 996–1005 (2008).
   PubMed Web of Science ®Google Scholar
• Wertheimer AI, Chaney NM, Santell T. Counterfeit pharmaceuticals: current status and future projections. J. Am. Pharm. Assoc.43(6), 710–718 (2003).
   Google Scholar
• Wertheimer AI. Identifying and combating counterfeit drugs. Expert Rev. Clin. Pharmacol.1(3), 333–336 (2008).
   PubMedGoogle Scholar
• Lybecker KM. Rx Roulette: combating counterfeit pharmaceuticals in developing nations. Manag. Decis. Econ.28, 509–520 (2007).
   Google Scholar
• Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med.5(1), e1 (2008).
   PubMed Web of Science ®Google Scholar
• Lichtenberg F, Philipson T. The dual effects of intellectual property regulations: within- and between-patent competition in the U.S. pharmaceuticals industry. J. Law Econ.45(2), 643–672 (2002).
   Web of Science ®Google Scholar
• Dorfman R, Steiner PO. Optimal advertising and optimal quality. Am. Econ. Rev.44, 826–836 (1954).
   Web of Science ®Google Scholar
• Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science280, 698–701 (1998).
   PubMed Web of Science ®Google Scholar
• Stix G. Owning the stuff of life. Sci. Am.294(2), 76–83 (2006).
   Google Scholar
• Roin BN. Unpatentable drugs and the standards of patentability. Texas Law Rev.87(3), 503–570 (2009).
   Web of Science ®Google Scholar
• Canada. The Report of the Commission of Inquiry on the Pharmaceutical Industry. Minister of Supply and Services, ON, Canada (1984).
   Google Scholar
• Stiglitz J. Scrooge and intellectual property rights: a medical prize fund could improve the financing of drug innovations. BMJ333, 1279–1280 (2006).
   PubMed Web of Science ®Google Scholar
• Kremer M. Pharmaceuticals and the developing world. J. Econ. Perspect.16, 67–90 (2002).
   PubMed Web of Science ®Google Scholar
• Guell R, Fischbaum M. Toward allocative efficiency in the prescription drug industry. Milbank Q.73, 213–229 (1995).
   PubMed Web of Science ®Google Scholar
• Kremer M. Patent buyouts: a mechanism for encouraging innovation. Q. J. Economics113, 1137–1167 (1998).
   Web of Science ®Google Scholar
• Landsburg SE. More Sex is Safer Sex: the Unconventional Wisdom of Economics. Free Press, MA, USA (2007).
   Google Scholar
• Baker D. The benefits and savings from publicly funded clinical trials of prescription drugs. Int. J. Health Serv.38(4), 731–750 (2008).
   PubMed Web of Science ®Google Scholar